TableĀ 4.
Outcome measures
Full name of assessment tool | Reasoning |
DBI14 |
|
InterRAI-LTCF29 |
|
EQ-5D-3L quality of life measure31 | This measure will be used to monitor the participants' quality of life during the study and has been used in a number of interventional studies in this population. It allows for economic evaluation. |
UKU-SERS32 | As we aim to deprescribe anticholinergic and sedative medicines (ie, which include psychotropic medicines) and we expect our participants to be prescribed a large amount of these medicines inappropriately, it is pertinent to choose an adverse effect rating scale such as the UKU-SERS, which specifically reports on the unwanted adverse effects associated with the use of psychotropic medicines. |
The rationale behind the use of these tools and assessments is summarised in table 4. Nurses will also be asked to monitor the appearance of specific ADWEs for each medicine to be deprescribed. Monitoring will be conducted for each individual and all ADWEs will be noted on the participant's MMP form.
ADL, activities of daily living; ADWE, adverse drug withdrawal effect; DBI, Drug Burden Index; EQ-5D-3L, EuroQoL 5-dimension 3-level; InterRAI-LTCF, InterRAI-Long Term Care Facilities; MMP, medication management plan; UKU-SERS, UKU-Side Effect Rating Scale.